Outcomes of hematologic malignancy patients with SARS-CoV-2 breakthrough infections after tixagevimab-cilgavimab during community transmission of monoclonal antibody resistant variants Research Letter

  

Authors:	Kamboj, M.; Laracy, J. C.; Usiak, S.; Babady, N. E.; Yan, J.; Seo, S. K.
Title:	Outcomes of hematologic malignancy patients with SARS-CoV-2 breakthrough infections after tixagevimab-cilgavimab during community transmission of monoclonal antibody resistant variants
Keywords:	adult; cancer chemotherapy; controlled study; aged; middle aged; leukemia; unclassified drug; human cell; major clinical study; prednisone; clinical feature; mortality; drug efficacy; nonhuman; united states; cancer patient; rituximab; follow up; antineoplastic agent; letter; computer assisted tomography; incidence; cohort analysis; odds ratio; dexamethasone; kidney failure; drug resistance; monoclonal antibody; hypoxia; cancer center; hospitalization; antibodies, monoclonal; disease severity; hematologic malignancy; myelodysplastic syndrome; hematologic neoplasms; adverse outcome; diabetes mellitus; lymphoma; comorbidity; predictor variable; methylprednisolone; multivariate analysis; antivirus agent; age distribution; hydrocortisone; bone marrow transplantation; univariate analysis; infection risk; lung infiltrate; parainfluenza virus infection; virus transmission; hematologic disease; myeloma; antiviral therapy; clinical outcome; ofatumumab; coinfection; ibrutinib; humans; human; male; female; tertiary care center; rebound; obinutuzumab; polatuzumab vedotin; chimeric antigen receptor t-cell immunotherapy; acalabrutinib; zanubrutinib; belantamab mafodotin; severe acute respiratory syndrome coronavirus 2; coronavirus disease 2019; covid-19; sars-cov-2; remdesivir; tafasitamab; pirtobrutinib; covid-19 vaccines; sars-cov-2 vaccine; cilgavimab plus tixagevimab; cilgavimab; tixagevimab; sars-cov-2 omicron; epcoritamab; loncastuximab tesirine; breakthrough infections; molnupiravir; nirmatrelvir plus ritonavir; breakthrough infection; covid-19 breakthrough infections; hyaluronidase plus rituximab; community transmission
Journal Title:	Journal of Infection
Volume:	87
Issue:	3
ISSN:	0163-4453
Publisher:	W.B. Saunders Co.
Date Published:	2023-09-01
Start Page:	282
End Page:	285
Language:	English
DOI:	10.1016/j.jinf.2023.06.024
PUBMED:	37451364
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85166662104&doi=10.1016%2fj.jinf.2023.06.024&partnerID=40&md5=b28ecfe623b1be5245526f98bb22f65c
Notes:	Letter -- MSK corresponding authors are Mini Kamboj and Justin Laracy -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/208765